FFO
IONS icon

Fortitude Family Office’s Ionis Pharmaceuticals IONS Stock Holding History

Fortitude Family Office’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35K Hold
17
– – ﹤0.01% 1636
2026
Q1 		$1.28K Hold
17
– – ﹤0.01% 1440
2025
Q4 		$1.34K Hold
17
– – ﹤0.01% 1336
2025
Q3 		$1.11K Hold
17
– – ﹤0.01% 1508
2025
Q2 		$672 Buy
+17
New +$556 ﹤0.01% 1672
2024
Q1 		– Sell
-14
Closed -$708 – 1036
2023
Q4 		$708 Buy
+14
New +$671 ﹤0.01% 963

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fortitude Family Office's IONS Position: Q2 2026 in Review

Fortitude Family Office held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 17 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Fortitude Family Office first reported a position in IONS in Q4 2023 and has held it in 6 quarters since. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Fortitude Family Office held 17 shares of Ionis Pharmaceuticals worth $1.35K as of Q2 2026.
  • Fortitude Family Office left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1636 holding.
  • Fortitude Family Office first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.